Advertisement

Der Pathologe

, Volume 40, Issue 1, pp 21–35 | Cite as

S3-Leitlinie Diagnostik und Therapie des Endometriumkarzinoms

Anforderungen an die Pathologie
  • L.-C. HornEmail author
  • G. Emons
  • S. Aretz
  • N. Bock
  • M. Follmann
  • S. Lax
  • M. Nothacker
  • E. Steiner
  • D. Mayr
  • Deutsche Krebsgesellschaft (DKG)
  • Kommission zur Erstellung der S3-Leitlinie „Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom“
Schwerpunkt: Gynäkopathologie

Zusammenfassung

Die vorliegende Übersicht fasst die relevanten Aspekte der S3-Leitlinie Endometriumkarzinom zusammen. Die Empfehlungen umfassen die Aufarbeitung und Befunderhebung bei Abrasionen und Präparaten der (radikalen) Hysterektomie sowie der Lymphonodektomien, einschließlich der Sentinel-Lymphknoten-Diagnostik. Die Leitlinie berücksichtigt neben praktischen Aspekten der Pathologie ebenso die klinischen Notwendigkeiten an die Histopathologie für eine optimale operative, strahlentherapeutische und adjuvante Therapie der Patientinnen. Karzinosarkome werde als besondere Variante dem Endometriumkarzinom zugeordnet. Erstmals wird ein Algorithmus zur Diagnostik des Lynch-Syndroms bei Patientinnen mit einem Endometriumkarzinoms definiert. Zusätzlich werden morphologische Prognosefaktoren zusammengefasst.

Schlüsselwörter

Endometriumkarzinom Sentinel-Lymphknoten Karzinosarkom Hereditäre nichtpolypöse kolorektale Karzinome Hysterektomie 

S3 guidelines on the diagnosis and treatment of carcinoma of the endometrium

Requirements for pathology

Abstract

The present article summarises the relevant aspects of the S3 guidelines on endometrioid carcinomas. The recommendations include the processing rules of fractional currettings as well as for hysterectomy specimens and lymph node resections (including sentinel lymph nodes). Besides practical aspects, the guidelines consider the needs of the clinicians for appropriate surgical and radiotherapeutic treatment of the patients. Carcinosarcomas are assigned to the endometrial carcinoma as a special variant. For the first time, an algorithmic approach for evaluation of the tumour tissue for Lynch syndrome is given. Prognostic factors based on morphologic findings are summarised.

Keywords

Endometrioid carcinoma Sentinel lymph node Carcinosarcoma Hereditary nonpolyposis colorectal neoplasms Hysterectomy 

Notes

Mitglieder der Kommission zur Erstellung der S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom

Prof. Dr. Bernd Alt-Epping, Göttingen; Prof. Dr. Stefan Aretz, Bonn; PD Dr. Dr. Gerd Bauerschmitz, Göttingen; Prof. Dr. Matthias W. Beckmann, Erlangen; Dr. Nina Bock, Göttingen; Dr. Wolfgang Cremer, Hamburg; Dr. Timm Dauelsberg, Nordrach; Prof. Dr. Günter Emons, Göttingen; Prof. Dr. Petra Feyer, Berlin; Prof. Dr. Markus Fleisch, Wuppertal; Prof. Dr. Michael Friedrich, Krefeld; Marion Gebhardt, Forchheim; Prof. Dr. Dieter Grab, München; Dr. Volker Hagen, Dortmund; Prof. Dr. Volker Hanf, Fürth; Ulla Henscher, Hannover; Prof. Dr. Felix Hilpert, Hamburg; Prof. Dr. Stefan Höcht, Saarlouis; Prof. Dr. Lars-Christian Horn, Leipzig; Prof. Dr. Jutta Hübner, Jena; Prof. Dr. Ingolf Juhasz-Böss, Homburg; Prof. Dr. Ludwig Kiesel, Münster; Prof. Dr. Rainer Kimmig, Essen; Prof. Dr. Michael Kreißl, Magdeburg; PD Dr. Christian Kurzeder, Basel; Prof. Dr. Jan Langrehr, Berlin; Prof. Dr. Sigurd Lax, Graz; Prof. Dr. Steffen Leinung, Grimma; PD Dr. Anne Letsch, Berlin; Prof. Dr. Werner Lichtenegger, Berlin; Prof. Dr. Peter Mallmann, Köln; Prof. Dr. Doris Mayr, München; Prof. Dr. Alfons Meindl, München; Prof. Dr. Jan Menke, Göttingen; Prof. Dr. Michael D. Mueller, Bern; Prof. Dr. Alexander Mustea, Greifswald; Prof. Dr. Peter Niehoff, Offenbach; Dr. Christiane Niehues, Berlin; Prof. Dr. Birgitt van Oorschot, Würzburg; Prof. Dr. Olaf Ortmann, Regensburg; Dr. Joan Elisabeth Panke, Essen; Kerstin Paradies, Hamburg; Prof. Dr. Edgar Petru, Graz; Prof. Dr. Heinrich Prömpeler, Freiburg; Prof. Dr. Franz-Josef Prott, Wiesbaden; Dr. Nils Rahner, Düsseldorf; Prof. Dr. Michael J. Reinhardt, Oldenburg; Dr. Anne D. Rose, Berlin; Prof. Dr. Ingo Runnebaum, MBA; Prof. Dr. Rita Katharina Schmutzler, Köln; Annemarie Schorsch, Bad Soden; Prof. Dr. Eric Steiner, Rüsselsheim; Dr. Verena Steinke-Lange, München; Prof. Dr. Vratislav Strnad, Erlangen; Prof. Dr. Clemens Tempfer, MBA, Herne; Reina Tholen, Bremen/Köln; Dr. Christoph Uleer, Hildesheim; Prof. Dr. Dirk Vordermark, Halle; Prof. Dr. Joachim B. Weis, Freiburg; PD Dr. Edward Wight, Basel; Dr. Ralf Witteler, Münster; Prof. Dr. Alain-Gustave Zeimet, Innsbruck

Einhaltung ethischer Richtlinien

Interessenkonflikt

L.-C. Horn, G. Emons, S. Aretz, N. Bock, M. Follmann, S. Lax, M. Nothacker, E. Steiner und D. Mayr geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Abu-Rustum NR, Zhou Q, Gomez JD, Alektiar KM, Hensley ML, Soslow RA, Levine DA, Chi DS, Barakat RR, Iasonos A (2010) A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol 116(3):399–403PubMedCrossRefGoogle Scholar
  2. 2.
    Ahmed QF, Gattoc L, Al-Wahab Z, Abdulfatah E, Ruterbusch JJ, Cote M, Bandyopadhyay S, Morris RT, Ali-Fehmi R (2015) Vanishing endometrial cancer in hysterectomy specimens: a myth or a fact. Am J Surg Pathol 39(2):221–226PubMedCrossRefGoogle Scholar
  3. 3.
    Ali A, Black D, Soslow RA (2007) Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol 26:115–123PubMedCrossRefGoogle Scholar
  4. 4.
    Altrabulsi B, Malpica A, Deavers MT, Bodurka DC, Broaddus R, Silva EG (2005) Undifferentiated carcinoma of the endometrium. Am J Surg Pathol 29(10):1316–1321PubMedCrossRefGoogle Scholar
  5. 5.
    Argani P, Cimino-Mathews A (2014) Intraoperative frozen sections. Diagnostic pitfalls. demosMedical, New York, S 255–258Google Scholar
  6. 6.
    AWMF (2014) S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom. AWMF-Leitliniennummer 032/033OL. http://www.awmf.org/uploads/tx_szleitlinien/032-033OLl_S3_Zervixkarzinom_2014-10.pdf. Zugegriffen: 24. Okt. 2018Google Scholar
  7. 7.
    AWMF (2015) S2k-Leitlinie zur Diagnostik, Therapie und Nachsorge des Vulvakarzinoms und seiner Vorstufen. AWMF-Leitliniennummer 015/059. http://www.awmf.org/uploads/tx_szleitlinien/015-059l_S2k_Vulvakarzinom_und_Vorstufen_Diagnostik_Therapie_2016-03_1.pdf. Zugegriffen: 24. Okt. 2018Google Scholar
  8. 8.
    Bartosch C, Lopes MJ, Oliva E (2011) Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Adv Anat Pathol 18(6):415–437PubMedCrossRefGoogle Scholar
  9. 9.
    Bendifallah S, Canlorbe G, Huguet F, Coutant C, Hudry D, Graesslin O, Raimond E, Touboul C, Collinet P, Bleu G, Daraï E, Ballester M (2014) A risk scoring system to determine recurrence in early-stage type 1 endometrial cancer: a French multicentre study. Ann Surg Oncol 21(13):4239–4245PubMedCrossRefGoogle Scholar
  10. 10.
    Bendifallah S, Canlorbe G, Raimond E, Bazire L, Huguet F, Graesslin O, Rouzier R, Darai E, Ballester M (2013) An external validation study of nomograms designed to predict isolated loco-regional and distant endometrial cancer recurrences: how applicable are they? Br J Cancer 109(6):1498–1503PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Bernardini MQ, Gien LT, Lau S, Altman AD, Gilks B, Ferguson SE, Köbel M, Samouëlian V, Wesa M, Cameron A, Nelson G, Han G, Clarke B, Ho TC, Panzarella T, Atenafu EG, McAlpine JN (2016) Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). Gynecol Oncol 141(1):148–154PubMedCrossRefGoogle Scholar
  12. 12.
    Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17PubMedCrossRefGoogle Scholar
  13. 13.
    Bosse T, Peters EE, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JW, Lutgens LC, van der Steen-Banasik EM, Smit VT, Nout RA (2015) Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer—a pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer 51(13):1742–1750PubMedCrossRefGoogle Scholar
  14. 14.
    Bubien V, Bonnet F, Brouste V, Hoppe S, Barouk-Simonet E, David A, Edery P, Bottani A, Layet V, Caron O, Gilbert-Dussardier B, Delnatte C, Dugast C, Fricker JP, Bonneau D, Sevenet N, Longy M, Caux F (2013) French Cowden Disease Network, High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 50(4):255–263PubMedCrossRefGoogle Scholar
  15. 15.
    Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM, Ferguson K, Arnold ST, Thompson BA, Lose FA, Parsons MT, Walters RJ, Pearson SA, Cummings M, Oehler MK, Blomfield PB, Quinn MA, Kirk JA, Stewart CJ, Obermair A, Young JP, Webb PM, Spurdle AB (2014) Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J Clin Oncol 32(2):90–100PubMedCrossRefGoogle Scholar
  16. 16.
    SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Villella J, Herzog T, Shahin AF, Society of Gynecologic Oncology Clinical Practice Committee (2014) Endmetrial cancer: a review and current management strategies: part I. Gynecol Oncol 134(2):385–392CrossRefGoogle Scholar
  17. 17.
    SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Herzog TJ, Shahin FA, Society of Gynecologic Oncology Clinical Practice Committee (2014) Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol 134(2):393–402CrossRefGoogle Scholar
  18. 18.
    Burleigh A, Talhouk A, Gilks CB, McAlpine JN (2015) Clinical and pathological characterization of endometrial cancer in young women: identification of a cohort without classical risk factors. Gynecol Oncol 138(1):141–146PubMedCrossRefGoogle Scholar
  19. 19.
    Cantrell LA, Blank SV, Duska LR (2015) Uterine carcinosarcoma: A review of the literature. Gynecol Oncol 137(3):581–588PubMedCrossRefGoogle Scholar
  20. 20.
    CAP: College of American Pathologists (2015) Protocol for the Examination of Specimens From Patients With Carcinoma of the Ovary. http://www.cap.org/web/oracle/webcenter/portalapp/pages/search-results.jspx?searchTerms=hysterectomy+omentectomy+peritoneal+biopsies+specify&_adf.ctrl-state=263oqd8k1_21&_afrLoop=629838432981632. Zugegriffen: 24. Okt. 2018Google Scholar
  21. 21.
    Chattopadhyay S, Galaal KA, Patel A, Fisher A, Nayar A, Cross P, Naik R (2012) Tumour-free distance from serosa is a better prognostic indicator than depth of invasion and percentage myometrial invasion in endometrioid endometrial cancer. BJOG 119(10):1162–1170PubMedCrossRefGoogle Scholar
  22. 22.
    Clarke BA, Cooper K (2012) Identifying Lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas. Adv Anat Pathol 19(4):231–238PubMedCrossRefGoogle Scholar
  23. 23.
    Clarke BA, Gilks CB (2010) Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol 63(5):410–415PubMedCrossRefGoogle Scholar
  24. 24.
    Cole AJ, Quick CM (2013) Patterns of myoinvasion in endometrial adenocarcinoma: recognition and implications. Adv Anat Pathol 20(3):141–147PubMedCrossRefGoogle Scholar
  25. 25.
    Colgan TJ, Hirschowitz L, Kim I, McCluggage WG (2014) Neuroendocrine tumours of the uterine cervix. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female reporductive tract. IARC Press, Lyon, S 196–198Google Scholar
  26. 26.
    Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C (2016) ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 27(1):16–41PubMedCrossRefGoogle Scholar
  27. 27.
    Cox Bauer CM, Greer DM, Kram JJ, Kamelle SA (2016) Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer. Gynecol Oncol 141(2):199–205PubMedCrossRefGoogle Scholar
  28. 28.
    Creutzberg CL, van Stiphout RG, Nout RA, Lutgens LC, Jürgenliemk-Schulz IM, Jobsen JJ, Smit VT, Lambin P (2015) Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. Int J Radiat Oncol Biol Phys 91(3):530–539PubMedCrossRefGoogle Scholar
  29. 29.
    Denschlag D, Thiel FC, Ackermann S, Harter P, Juhasz-Boess I, Mallmann P, Strauss HG, Ulrich U, Horn LC, Schmidt D, Vordermark D, Vogl T, Reichardt P, Gaß P, Gebhardt M, Beckmann MW (2015) Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015). Geburtshilfe Frauenheilkd 75(10):1028–1042PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Egoavil C, Alenda C, Castillejo A, Paya A, Peiro G, Sánchez-Heras AB, Castillejo MI, Rojas E, Barberá VM, Cigüenza S, Lopez JA, Piñero O, Román MJ, Martínez-Escoriza JC, Guarinos C, Perez-Carbonell L, Aranda FI, Soto JL (2013) Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers. PLoS ONE 8(11):e79737PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Elshaikh MA, Al-Wahab Z, Mahdi H, Albuquerque K, Mahan M, Kehoe SM, Ali-Fehmi R, Rose PG, Munkarah AR (2015) Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study. Gynecol Oncol 136(2):235–239PubMedCrossRefGoogle Scholar
  32. 32.
    Euscher E, Fox P, Bassett R, Al-Ghawi H, Ali-Fehmi R, Barbuto D, Djordjevic B, Frauenhoffer E, Kim I, Hong SR, Montiel D, Moschiano E, Roma A, Silva E, Malpica A (2013) The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma. Am J Surg Pathol 37(11):1728–1736PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Ferguson SE, Aronson M, Pollett A, Eiriksson LR, Oza AM, Gallinger S, Lerner-Ellis J, Alvandi Z, Bernardini MQ, MacKay HJ, Mojtahedi G, Tone AA, Massey C, Clarke BA (2014) Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer 120(24):3932–3939PubMedCrossRefGoogle Scholar
  34. 34.
    Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA (2007) Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 31(11):1653–1661PubMedCrossRefGoogle Scholar
  35. 35.
    Ferraioli D, Chopin N, Beurrier F, Carrabin N, Buenerd A, Mathevet P (2015) The incidence and clinical significance of the micrometastases in the sentinel lymph nodes during surgical staging for early endometrial cancer. Int J Gynecol Cancer 25(4):673–680PubMedCrossRefGoogle Scholar
  36. 36.
    Fujii H, Yoshida M, Gong ZX, Matsumoto T, Hamano Y, Fukunaga M, Hruban RH, Gabrielson E, Shirai T (2000) Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 60(1):114–120PubMedGoogle Scholar
  37. 37.
    Galic V, Schiavone MB, Herzog TJ, Holcomb K, Lewin SN, Lu YS, Neugut AI, Hershman DL, Wright JD (2013) Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium. Cancer Invest 31(7):500–504PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Geels YP, Pijnenborg JM, van den Berg-van Erp SH, Bulten J, Visscher DW, Dowdy SC, Massuger LF (2012) Endometrioid endometrial carcinoma with atrophic endometrium and poor prognosis. Obstet Gynecol 120(5):1124–1131PubMedGoogle Scholar
  39. 39.
    Geels YP, Pijnenborg JM, van den Berg-van Erp SH, Snijders MP, Bulten J, Massuger LF (2013) Absolute depth of myometrial invasion in endometrial cancer is superior to the currently used cut-off value of 50. Gynecol Oncol 129(2):285–291PubMedCrossRefGoogle Scholar
  40. 40.
    Geels YP, van der Putten LJ, van Tilborg AA, Lurkin I, Zwarthoff EC, Pijnenborg JM, van den Berg-van Erp SH, Snijders MP, Bulten J, Visscher DW, Dowdy SC, Massuger LF (2015) Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium. Gynecol Oncol 137(2):245–251PubMedCrossRefGoogle Scholar
  41. 41.
    Gungorduk K, Ozdemir A, Ertas IE, Selcuk I, Solmaz U, Ozgu E, Mat E, Gokcu M, Karadeniz T, Akbay S, Sanci M, Meydanli MM, Ayaz D, Gungor T (2015) Is mucinous adenocarcinoma of the endometrium a risk factor for lymph node involvement? A multicenter case-control study. Int J Clin Oncol 20(4):782–789PubMedCrossRefGoogle Scholar
  42. 42.
    Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, La Jeunesse J, Nakagawa H, Westman JA, Prior TW, Clendenning M, Penzone P, Lombardi J, Dunn P, Cohn DE, Copeland L, Eaton L, Fowler J, Lewandowski G, Vaccarello L, Bell J, Reid G, de la Chapelle A (2006) Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66(15):7810–7817PubMedCrossRefGoogle Scholar
  43. 43.
    Hampel H, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, LaJeunesse J, Nakagawa H, Westman JA, Prior TW, Clendenning M, de la Chapelle A, Frankel W, Penzone P, Cohn DE, Copeland L, Eaton L, Fowler J, Lombardi J, Dunn P, Bell J, Reid G, Lewandowski G, Vaccarello L (2007) Comment on: screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 67(19):9603PubMedCrossRefGoogle Scholar
  44. 44.
    Han G, Lim D, Leitao MM Jr, Abu-Rustum NR, Soslow RA (2014) Histological features associated with occult lymph node metastasis in FIGO clinical stage I, grade I endometrioid carcinoma. Histopathology 64(3):389–398PubMedCrossRefGoogle Scholar
  45. 45.
    Hanley KZ, Fadare O, Fisher KE, Atkins KA, Mosunjac MB (2016) Clinical significance of positive pelvic washings in uterine papillary serous carcinoma confined to an endometrial polyp. Int J Gynecol Pathol 35(3):249–255PubMedCrossRefGoogle Scholar
  46. 46.
    Hertel JD, Huettner PC, Pfeifer JD (2014) Lymphovascular space invasion in microcystic elongated and fragmented (MELF)-pattern well-differentiated endometrioid adenocarcinoma is associated with a higher rate of lymph node metastasis. Int J Gynecol Pathol 33(2):127–134PubMedCrossRefGoogle Scholar
  47. 47.
    Hirschowitz L, Nucci M, Zaino RJ (2013) Problematic issues in the staging of endometrial, cervical and vulval carcinomas. Histopathology 62(1):176–202PubMedCrossRefGoogle Scholar
  48. 48.
    Hoekstra AV, Kim RJ, Small W Jr, Rademaker AW, Helenowski IB, Singh DK, Schink JC, Lurain JR (2009) FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes. Gynecol Oncol 114(2):273–278PubMedCrossRefGoogle Scholar
  49. 49.
    Horn LC, Beckmann MW, Follmann M, Koch MC, Mallmann P, Marnitz S, Schmidt D, German Cancer Society (2015) S3 guidelines on diagnostics and treatment of cervical cancer: Demands on pathology. Pathologe 36(6):585–593PubMedCrossRefGoogle Scholar
  50. 50.
    Horn LC, Dallacker M, Bilek K (2009) Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors. Pathologe 30(4):292–301PubMedCrossRefGoogle Scholar
  51. 51.
    Horn LC, Mayr D, Brambs CE, Einenkel J, Sändig I, Schierle K (2016) Grading of gynecological tumors : current aspects. Pathologe 37(4):337–351PubMedCrossRefGoogle Scholar
  52. 52.
    Horn LC, Schnurrbusch U, Bilek K, Hentschel B, Einenkel J (2004) Risk of progression in complex an atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer 14(2):348–353PubMedCrossRefGoogle Scholar
  53. 53.
    Horn LC, Trost M, Bilek K (2010) Staging of endometrial carcinoma: aspects of ovarian and cervical involvement. Int J Gynecol Pathol 29(1):63–66PubMedCrossRefGoogle Scholar
  54. 54.
    Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S, Auranen A (2013) Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Gynecol Oncol 130(3):463–469PubMedCrossRefGoogle Scholar
  55. 55.
    Jongen V, Briët J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H, Hollema H (2009) Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 112(3):537–542PubMedCrossRefGoogle Scholar
  56. 56.
    Jorge S, Hou JY, Tergas AI, Burke WM, Huang Y, Hu JC, Ananth CV, Neugut AI, Hershman DL, Wright JD (2016) Magnitude of risk for nodal metastasis associated with lymphvascular space invasion for endometrial cancer. Gynecol Oncol 140(3):387–393PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Kalyanasundaram K, Ganesan R, Perunovic B, McCluggage WG (2010) Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis. Int J Surg Pathol 18(2):138–143PubMedCrossRefGoogle Scholar
  58. 58.
    Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L (2013) Mutational landscape and significance across 12 major cancer types. Nature 502(7471):333–339PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Kim HJ, Kim TJ, Song T, Kim MK, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG (2012) Patterns of recurrence in endometrial cancer patients at risk of lymph node metastasis or recurrence according to extent of lymphadenectomy. Int J Gynecol Cancer 22(4):611–616PubMedCrossRefGoogle Scholar
  60. 60.
    Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis A, Yang W, Lum A, Krämer B, Taran F, Staebler A, Lax S, Brucker SY, Huntsman DG, Gilks CB, McAlpine JN, Talhouk A (2018) Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 29(5):1180–1188PubMedCrossRefGoogle Scholar
  61. 61.
    Kommoss FK, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, Gilks CB, Huntsman DG, Krämer B, Brucker SY, McAlpine JN, Kommoss S (2018) L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer 119(4):480–486PubMedCrossRefGoogle Scholar
  62. 62.
    Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RB, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Kurman RJ, Levine DA, Wang TL, Shih IeM (2012) Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 104(19):1503–1513PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Kumar S, Bandyopadhyay S, Semaan A, Shah JP, Mahdi H, Morris R, Munkarah A, Ali-Fehmi R (2011) The role of frozen section in surgical staging of low risk endometrial cancer. PLoS ONE 6(9):e21912PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Kurman RJ, Kaminski PF, Norris HJ (1985) The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 56(2):403–412PubMedCrossRefGoogle Scholar
  65. 65.
    Kyrgiou M, Chatterjee J, Lyus R, Amin T, Ghaem-Maghami S (2013) The role of cytology and other prognostic factors in endometrial cancer. J Obstet Gynaecol 33(7):729–734PubMedCrossRefGoogle Scholar
  66. 66.
    Lacey JV Jr, Chia VM (2009) Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas 63(1):39–44PubMedCrossRefGoogle Scholar
  67. 67.
    Leenen CH, van Lier MG, van Doorn HC, van Leerdam ME, Kooi SG, de Waard J, Hoedemaeker RF, van den Ouweland AM, Hulspas SM, Dubbink HJ, Kuipers EJ, Wagner A, Dinjens WN, Steyerberg EW (2012) Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years. Gynecol Oncol 125(2):414–420PubMedCrossRefGoogle Scholar
  68. 68.
    Lopez-Garcia MA, Palacios J (2010) Pathologic and molecular features of uterine carcinosarcomas. Semin Diagn Pathol 27(4):274–286PubMedCrossRefGoogle Scholar
  69. 69.
    Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen LM, Allen B, Conrad P, Terdiman J, Sun C, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR (2005) Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 105(3):569–574PubMedCrossRefGoogle Scholar
  70. 70.
    Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR (2007) Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 25(33):5158–5164PubMedCrossRefGoogle Scholar
  71. 71.
    Mahdi H, Mester JL, Nizialek EA, Ngeow J, Michener C, Eng C (2015) Germline PTEN, SDHB-D, and KLLN Alterations in Endometrial Cancer Patients With Cowden and Cowden-Like Syndromes: An International, Multicenter, Prospective Study. Cancer 121(5):688–696PubMedCrossRefGoogle Scholar
  72. 72.
    Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Muñoz J, Argüelles R, Machin P, Prat J (2001) Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 32(6):569–577PubMedCrossRefGoogle Scholar
  73. 73.
    Mauland KK, Wik E, Salvesen HB (2014) Clinical value of DNA content assessment in endometrial cancer. Cytometry B Clin Cytom 86(3):154–163PubMedCrossRefGoogle Scholar
  74. 74.
    McCluggage WG, Colgan T, Duggan M, Hacker NF, Mulvany N, Otis C, Wilkinson N, Zaino RJ, Hirschowitz L (2013) Data set for reporting of endometrial carcinomas: recommendations from the International Collaboration on Cancer Reporting (ICCR) between United Kingdom, United States, Canada, and Australasia. Int J Gynecol Pathol 32(1):45–65PubMedCrossRefGoogle Scholar
  75. 75.
    McCluggage WG, Hirschowitz L, Wilson GE, Oliva E, Soslow RA, Zaino RJ (2011) Significant variation in the assessment of cervical involvement in endometrial carcinoma: an interobserver variation study. Am J Surg Pathol 35(2):289–294PubMedCrossRefGoogle Scholar
  76. 76.
    McCluggage WG, Judge MJ, Clarke BA, Davidson B, Gilks CB, Hollema H, Ledermann JA, Matias-Guiu X, Mikami Y, Stewart CJ, Vang R, Hirschowitz L (2015) Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol 28(8):1101–1122PubMedCrossRefGoogle Scholar
  77. 77.
    Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230–236PubMedCrossRefGoogle Scholar
  78. 78.
    Meng B, Hoang LN, McIntyre JB, Duggan MA, Nelson GS, Lee CH, Köbel M (2014) POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol 134(1):15–19PubMedCrossRefGoogle Scholar
  79. 79.
    Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E (2016) Endometrial cancer. Lancet 387(10023):1094–1108PubMedCrossRefGoogle Scholar
  80. 80.
    Movahedi-Lankarani S, Gilks CB, Soslow R, Oliva E, Members of the Cancer Committee, College of American Pathologists Protocol for the Examination of Specimens from Patients with Carcinoma of the Endometrium. http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2011/Endometrium_11protocol.doc. Zugegriffen: 24. Okt. 2018Google Scholar
  81. 81.
    Nakao Y, Yamasaki F, Yokoyama M, Aihara S, Yasunaga M, Iwasaka T (2014) Minimal deviation endometrioid adenocarcinoma of the endometrium and its MRI findings. Eur J Gynaecol Oncol 35(2):185–187PubMedGoogle Scholar
  82. 82.
    Orezzoli JP, Sioletic S, Olawaiye A, Oliva E, del Carmen MG (2009) Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion. Gynecol Oncol 113(3):316–323PubMedCrossRefGoogle Scholar
  83. 83.
    Ozturk E, Dikensoy E, Balat O, Ugur MG, Aydin A (2012) Intraoperative frozen section is essential for assessment of myometrial invasion but not for histologic grade confirmation in endometrial cancer: a ten-year experience. Arch Gynecol Obstet 285(5):1415–1419PubMedCrossRefGoogle Scholar
  84. 84.
    Pacaut C, Bourmaud A, Rivoirard R, Moriceau G, Guy JB, Collard O, Bosacki C, Jacquin JP, Levy A, Chauleur C, Magné N, Merrouche Y (2015) Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy. Am J Clin Oncol 38(3):272–277PubMedCrossRefGoogle Scholar
  85. 85.
    Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104PubMedCrossRefGoogle Scholar
  86. 86.
    Pocrnich CE, Ramalingam P, Euscher ED, Malpica A (2016) Neuroendocrine carcinoma of the endometrium: a clinicopathologic study of 25 cases. Am J Surg Pathol 40(5):577–586PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Pollom EL, Conklin CM, von Eyben R, Folkins AK, Kidd EA (2016) Nomogram to predict risk of lymph node metastases in patients with endometrioid endometrial cancer. Int J Gynecol Pathol 35(5):395–401PubMedCrossRefGoogle Scholar
  88. 88.
    Pradhan M, Abeler VM, Danielsen HE, Sandstad B, Tropé CG, Kristensen GB, Risberg BÅ (2012) Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium. Ann Oncol 23(5):1178–1184PubMedCrossRefGoogle Scholar
  89. 89.
    Quddus MR, Sung CJ, Zhang C, Lawrence WD (2010) Minor serous and clear cell components adversely affect prognosis in “mixed-type” endometrial carcinomas: a clinicopathologic study of 36 stage-I cases. Reprod Sci 17(7):673–678PubMedCrossRefGoogle Scholar
  90. 90.
    Robboy SJ, Mutter GL, Shako-Levy R, Bean SM, Prat J, Bentley RC, Russel P (2009) Cutup—gross description and processing of specimens. In: Robboy SJ, Mutter GL, Prat J, Bentley RC, Russel P, Anderson MC (Hrsg) Robboy’s pathology of the female reproductive tract. Elsevier, Edinburgh, London, New York, Oxford, Philadelphia, St. Louis, Sydney, Toronto, S 979–991CrossRefGoogle Scholar
  91. 91.
    Roelofsen T, van Ham MA, Wiersma van Tilburg JM, Zomer SF, Bol M, Massuger LF, Bulten J (2012) Pure compared with mixed serous endometrial carcinoma: two different entities? Obstet Gynecol 120(6):1371–1381PubMedCrossRefGoogle Scholar
  92. 92.
    Rauh-Hain JA, Vargas RJ, Clemmer J, Clark RM, Bradford LS, Growdon WB, Goodman A, Boruta DM 2nd, Schorge JO, del Carmen MG (2016) Mucinous Adenocarcinoma of the Endometrium Compared With Endometrioid Endometrial Cancer: A SEER Analysis. Am J Clin Oncol 39(1):43–48PubMedCrossRefGoogle Scholar
  93. 93.
    Sakai K, Yamagami W, Susumu N, Nomura H, Kataoka F, Banno K, Tsuda H, Aoki D (2015) Pathological factors associated with omental metastases in endometrial cancer. Eur J Gynaecol Oncol 36(4):397–401PubMedGoogle Scholar
  94. 94.
    SGO Society of Gynecologic Oncologists (2005) Clinical practice committee statement on prohpylactic salpingo-oophorectomy. Gynecol Oncol 98:179–181CrossRefGoogle Scholar
  95. 95.
    Shaw PA, Clarke BA (2016) Prophylactic gynecologic specimens from hereditary cancer carriers. Surg Pathol Clin 9(2):307–328PubMedCrossRefGoogle Scholar
  96. 96.
    Shiozaki T, Tabata T, Yamada T, Yamamoto Y, Yamawaki T, Ikeda T (2014) Does positive peritoneal cytology not affect the prognosis for stage I uterine endometrial cancer?: the remaining controversy and review of the literature. Int J Gynecol Cancer 24(3):549–555PubMedCrossRefGoogle Scholar
  97. 97.
    Sho T, Hachisuga T, Nguyen TT, Urabe R, Kurita T, Kagami S, Kawagoe T, Matsuura Y, Shimajiri S (2014) Expression of estrogen receptor-α as a prognostic factor in patients with uterine serous carcinoma. Int J Gynecol Cancer 24(1):102–106PubMedCrossRefGoogle Scholar
  98. 98.
    Singh R (2014) Review literature on uterine carcinosarcoma. J Cancer Res Ther 10(3):461–468PubMedGoogle Scholar
  99. 99.
    Soslow RA (2013) High-grade endometrial carcinomas—strategies for typing. Histopathology 62(1):89–110PubMedCrossRefGoogle Scholar
  100. 100.
    Skala SL, Hagemann IS (2015) Optimal sampling of grossly normal omentum in staging of gynecologic malignancies. Int J Gynecol Pathol 34(3):281–287PubMedCrossRefGoogle Scholar
  101. 101.
    Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C (2014) A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technol Assess 18(58):1–406PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Clair StCM, Eriksson AG, Ducie JA, Jewell EL, Alektiar KM, Hensley ML, Soslow RA, Abu-Rustum NR, Leitao MM Jr (2016) Low-volume lymph node metastasis discovered during sentinel lymph node mapping for endometrial carcinoma. Ann Surg Oncol 23(5):1653–1659CrossRefGoogle Scholar
  103. 103.
    Steiner E, Einenkel J, Schmidt D, Horn LC (2012) Prädiktive und prognostische Marker beim Endometriumkarzinom. Onkologe 18:853–865CrossRefGoogle Scholar
  104. 104.
    Stephan JM, Hansen J, Samuelson M, McDonald M, Chin Y, Bender D, Reyes HD, Button A, Goodheart MJ (2014) Intra-operative frozen section results reliably predict final pathology in endometrial cancer. Gynecol Oncol 133(3):499–505PubMedCrossRefGoogle Scholar
  105. 105.
    Syed S, Reed N, Millan D (2015) Adequacy of cervical sampling in hysterectomy specimens for endometrial cancer. Ann Diagn Pathol 19(2):43–44PubMedCrossRefGoogle Scholar
  106. 106.
    Takano M, Ochi H, Takei Y, Miyamoto M, Hasumi Y, Kaneta Y, Nakamura K, Kurosaki A, Satoh T, Fujiwara H, Nagao S, Furuya K, Yokota H, Ito K, Minegishi T, Yoshikawa H, Fujiwara K, Suzuki M (2013) Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)? Br J Cancer 109(7):1760–1765PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Talhouk A, Hoang LN, McConechy MK, Nakonechny Q, Leo J, Cheng A, Leung S, Yang W, Lum A, Köbel M, Lee CH, Soslow RA, Huntsman DG, Gilks CB, McAlpine JN (2016) Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. Gynecol Oncol 143(1):46–53PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN (2017) Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123(5):802–813PubMedCrossRefGoogle Scholar
  109. 109.
    Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks B, Anglesio MS, Nelson BH, McAlpine JN (2018) Molecular subtype not immune response drives outcomes in endometrial carcinoma. Clin Cancer Res:6.  https://doi.org/10.1158/1078-0432.CCR-18-3241 CrossRefPubMedGoogle Scholar
  110. 110.
    Tejerizo-García A, Jiménez-López JS, Muñoz-González JL, Bartolomé-Sotillos S, Marqueta-Marqués L, López-González G, Gómez JF (2013) Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients. Onco Targets Ther 9:1305–1313PubMedGoogle Scholar
  111. 111.
    Todo Y, Kato H, Okamoto K, Minobe S, Yamashiro K, Sakuragi N (2016) Isolated tumor cells and micrometastases in regional lymph nodes in stage I to II endometrial cancer. J Gynecol Oncol 27(1):e1PubMedCrossRefGoogle Scholar
  112. 112.
    Torres ML, Weaver AL, Kumar S, Uccella S, Famuyide AO, Cliby WA, Dowdy SC, Gostout BS, Mariani A (2012) Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol 120(5):998–1004PubMedPubMedCentralGoogle Scholar
  113. 113.
    Touboul C, Bentivegna E, Uzan C, Gouy S, Pautier P, Lhommé C, Duvillard P, Haie-Meder C, Morice P (2013) Sentinel lymph node in endometrial cancer: a review. Curr Oncol Rep 15(6):559–565PubMedCrossRefGoogle Scholar
  114. 114.
    Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Higgins R, Zaino R, Mutter GL (2012) Society of gynecologic oncology clinical practice committee. Management of endometrial precancers. Obstet Gynecol 120(5):1160–1175PubMedPubMedCentralGoogle Scholar
  115. 115.
    Turan T, Oguz E, Unlubilgin E, Tulunay G, Boran N, Demir OF, Kose MF (2013) Accuracy of frozen-section examination for myometrial invasion and grade in endometrial cancer. Eur J Obstet Gynecol Reprod Biol 167(1):90–95PubMedCrossRefGoogle Scholar
  116. 116.
    Ulker V, Tunca A, Numanoglu C, Akbayir O, Akyol A, Erim A, Ongut C (2014) Should omentectomy be a part of surgical staging in patients with endometrioid adenocarcinoma of the uterine corpus? Gynecol Obstet Invest 77(1):58–63PubMedCrossRefGoogle Scholar
  117. 117.
    Vargas R, Rauh-Hain JA, Clemmer J, Clark RM, Goodman A, Growdon WB, Schorge JO, Del Carmen MG, Horowitz NS, Boruta DM 2nd (2014) Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol 133(2):216–220PubMedCrossRefGoogle Scholar
  118. 118.
    Vidal F, Rafii A (2013) Lymph node assessment in endometrial cancer: towards personalized medicine. Obstet Gynecol Int 2013:892465PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    Williams JW, Hirschowitz L (2006) Assessment of uterine wall thickness and position of the vascular plexus in the deep myometrium: implications for the measurement of depth of myometrial invasion of endometrial carcinomas. Int J Gynecol Pathol 25(1):59–64PubMedCrossRefGoogle Scholar
  120. 120.
    Wittekind C, Meyer HJ (2011) TNM-Klassifikation maligner Tumoren. Endometriumkarzinom. Wiley-Blackwell, Weinheim, S 198–202Google Scholar
  121. 121.
    Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K, Herzog TJ (2012) Contemporary management of endometrial cancer. Lancet 379(9823):1352–1360PubMedCrossRefGoogle Scholar
  122. 122.
    Zaino R, Carinelli SG, Ellenson LH, Rng C, Katabuchi H, Konishi I, Lax S, Matias-Giu X, Mutter GL, Peters WA, Sherman ME, Shih IM, Soslow R, Stewart CJR (2014) Epitehlail tumors and precursosr of the endometrium. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female Reporductive tract. IARC Press, Lyon, S 125–135Google Scholar
  123. 123.
    Zaino RJ, Abendroth C, Yemelyanova A, Oliva E, Lim D, Soslow R, Delair D, Hagemann IS, Montone K, Zhu J (2013) Endocervical involvement in endometrial adenocarcinoma is not prognostically significant and the pathologic assessment of the pattern of involvement is not reproducible. Gynecol Oncol 128(1):83–87PubMedCrossRefGoogle Scholar
  124. 124.
    Zaino RJ (2009) FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol 28:1–9PubMedCrossRefGoogle Scholar
  125. 125.
    Zaino RJ (2014) Unusual patterns of endometrial carcinoma including MELF and its relation to epithelial mesenchymal transition. Int J Gynecol Pathol 33(4):357–364PubMedCrossRefGoogle Scholar
  126. 126.
    Zannoni GF, Monterossi G, De Stefano I, Gargini A, Salerno MG, Farulla I, Travaglia D, Vellone VG, Scambia G, Gallo D (2013) The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer. Hum Pathol 44(6):1047–1054PubMedCrossRefGoogle Scholar
  127. 127.
    Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M (2013) L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 105(15):1142–1150PubMedCrossRefGoogle Scholar
  128. 128.
    Zheng W, Schwartz PE (2005) Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol Oncol 96(3):579–582PubMedCrossRefGoogle Scholar
  129. 129.
    Zhu J, Wen H, Bi R, Wu X (2016) Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study. J Gynecol Oncol 27(2):e18PubMedCrossRefGoogle Scholar

Copyright information

© Leitlinienprogramm Onkologie 2019

Authors and Affiliations

  • L.-C. Horn
    • 1
    Email author
  • G. Emons
    • 2
  • S. Aretz
    • 3
  • N. Bock
    • 2
  • M. Follmann
    • 4
  • S. Lax
    • 5
  • M. Nothacker
    • 6
  • E. Steiner
    • 7
  • D. Mayr
    • 8
  • Deutsche Krebsgesellschaft (DKG)
    • 4
  • Kommission zur Erstellung der S3-Leitlinie „Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom“
  1. 1.Abteilung Mamma‑, Gynäko- & Perinatalpathologie, Institut für PathologieUniversitätsklinikum Leipzig AöRLeipzigDeutschland
  2. 2.FrauenklinikUniversitätsmedizin GöttingenGöttingenDeutschland
  3. 3.Institut für HumangenetikUniversitätsklinikum BonnBonnDeutschland
  4. 4.Deutsche KrebsgesellschaftBerlinDeutschland
  5. 5.Institut für PathologieLandeskrankenhaus Graz WestGrazÖsterreich
  6. 6.Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)BerlinDeutschland
  7. 7.FrauenklinikGPR Klinikum RüsselsheimRüsselsheimDeutschland
  8. 8.Pathologisches Institut, Medizinische FakultätLudwig-Maximilians-Universität MünchenMünchenDeutschland

Personalised recommendations